Targeting CD25-positive Leukemic Stem cells (LSCs) and triggering Treg depletion using ALD25_ADC
ALD25_ADC is a first-In-Class CD25_ADC asset incorporating Alderaan’s IL2-sparing and CD25-specific antibody and a state-of-the-art linker/conjugation technology. ALD25-ADC has shown strong in vitro and in vivo proof-of-concept in CD25+ lymphoma models.
ALD25_ADC is developed for the treatment of Acute Myeloid Leukemia (AML) and T cell malignancies (CTCL, PTCL) where high unmet need in early lines of treatment still exists and where there is a high unmet medical need in early lines of treatment and where bispecific and CAR-T approaches still fail to provide strong clinical benefit. In AML, CD25 expression in found in more than 30% of patients and is particularly associated with the FLT3-ITD mutation. CD25 is expressed by chemo-resistant Leukemic stem cells and is also increased in AML blasts after treatment with standard of care Venetoclax + hypomethylating agents. In CTCL and PTCL, CD25 is highly expressed on T-cell blasts in 30 to 50% of patients.
Alderaan’s CD25 specific antibody spares IL-2 signaling and efficiently target Treg cells, favoring the development of host immune responses against cancer cells in both hematologic malignancies and solid cancer. Moreover, In vitro and in vivo proof of concepts of Treg depletion have been achieved allowing long-term cure in multiple mouse models of solid cancers.